| | ||||||||||||||
Title of Each Class of Securities Offered
|
| | |
Maximum Aggregate
Offering Price |
| | |
Amount of
Registration Fee(1) |
| ||||||
0.300% Notes due 2023
|
| | | | $ | 1,400,000,000 | | | | | | $ | 152,740 | | |
3.000% Notes due 2051
|
| | | | $ | 750,000,000 | | | | | | $ | 81,825 | | |
0.700% Notes due 2024
|
| | | | $ | 1,600,000,000 | | | | | | $ | 174,560 | | |
Guarantees of 0.700% Notes due 2024(2)
|
| | | | | — | | | | | | | — | | |
1.200% Notes due 2026
|
| | | | $ | 1,250,000,000 | | | | | | $ | 136,375 | | |
Guarantees of 1.200% Notes due 2026(2)
|
| | | | | — | | | | | | | — | | |
1.750% Notes due 2028
|
| | | | $ | 1,250,000,000 | | | | | | $ | 136,375 | | |
Guarantees of 1.750% Notes due 202(2)
|
| | | | | — | | | | | | | — | | |
2.250% Notes due 2031
|
| | | | $ | 750,000,000 | | | | | | $ | 81,825 | | |
Guarantees of 2.250% Notes due 2031(2)
|
| | | | | — | | | | | | | — | | |
Total
|
| | | | $ | 7,000,000,000 | | | | | | $ | 763,700 | | |
|
AstraZeneca PLC
$1,400,000,000 0.300% Notes due 2023
$750,000,000 3.000% Notes due 2051 |
| |
AstraZeneca Finance LLC
$1,600,000,000 0.700% Notes due 2024
$1,250,000,000 1.200% Notes due 2026 $1,250,000,000 1.750% Notes due 2028 $750,000,000 2.250% Notes due 2031 |
|
| | | |
fully and unconditionally guaranteed by AstraZeneca PLC
|
|
| | |
Price to
Public(1) |
| |
Underwriting
Discounts |
| |
Proceeds to Issuer
(before expenses) |
| |||||||||
Per AZ PLC 2023 Note
|
| | | | 99.911% | | | | | | 0.100% | | | | | | 99.811% | | |
Total for AZ PLC 2023 Notes
|
| | | $ | 1,398,754,000 | | | | | $ | 1,400,000 | | | | | $ | 1,397,354,000 | | |
Per AZ PLC 2051 Note
|
| | | | 98.634% | | | | | | 0.650% | | | | | | 97.984% | | |
Total for AZ PLC 2051 Notes
|
| | | $ | 739,755,000 | | | | | $ | 4,875,000 | | | | | $ | 734,880,000 | | |
Per AZ Finance 2024 Note
|
| | | | 99.991% | | | | | | 0.125% | | | | | | 99.866% | | |
Total for AZ Finance 2024 Notes
|
| | | $ | 1,599,856,000 | | | | | $ | 2,000,000 | | | | | $ | 1,597,856,000 | | |
Per AZ Finance 2026 Note
|
| | | | 99.874% | | | | | | 0.225% | | | | | | 99.649% | | |
Total for AZ Finance 2026 Notes
|
| | | $ | 1,248,425,000 | | | | | $ | 2,812,500 | | | | | $ | 1,245,612,500 | | |
Per AZ Finance 2028 Note
|
| | | | 99.830% | | | | | | 0.275% | | | | | | 99.555% | | |
Total for AZ Finance 2028 Notes
|
| | | $ | 1,247,875,000 | | | | | $ | 3,437,500 | | | | | $ | 1,244,437,500 | | |
Per AZ Finance 2031 Note
|
| | | | 99.875% | | | | | | 0.325% | | | | | | 99.550% | | |
Total for AZ Finance 2031 Notes
|
| | | $ | 749,062,500 | | | | | $ | 2,437,500 | | | | | $ | 746,625,000 | | |
Total
|
| | | $ | 6,983,727,500 | | | | | $ | 16,962,500 | | | | | $ | 6,966,765,000 | | |
| Goldman Sachs & Co. LLC | | |
J.P. Morgan
|
| |
Morgan Stanley
|
|
| Barclays | | |
BNP Paribas
|
| |
Citigroup
|
| |
Deutsche Bank Securities
|
| |
HSBC
|
|
| Mizuho Securities | | |
Santander
|
| |
SEB
|
| |
Société Générale
|
|
| | |
Page
|
| |||
Prospectus Supplement
|
| ||||||
| | | | S-iii | | | |
| | | | S-iii | | | |
| | | | S-iii | | | |
| | | | S-vi | | | |
| | | | S-1 | | | |
| | | | S-11 | | | |
| | | | S-17 | | | |
| | | | S-18 | | | |
| | | | S-19 | | | |
| | | | S-25 | | | |
| | | | S-32 | | | |
| | | | S-34 | | | |
| | | | S-35 | | | |
| | | | S-38 | | | |
| | | | S-42 | | | |
| | | | S-42 | | |
|
Prospectus
|
| ||||||
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 14 | | | |
| | | | | 31 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 37 | | | |
| | | | | 44 | | | |
| | | | | 46 | | | |
| | | | | 46 | | |
| | |
As at
March 31, 2021 |
| |||||||||
| | |
Actual
|
| |
As Adjusted(1)
|
| ||||||
| | |
(Unaudited, in $ millions)
|
| |||||||||
Cash and cash equivalents
|
| | | | 7,636 | | | | | | 14,603 | | |
Current loans and borrowings
|
| | | | | | | | | | | | |
Current installments of loans and bonds
|
| | | | 1,461 | | | | | | 1,461 | | |
Current installments of leases
|
| | | | 216 | | | | | | 216 | | |
Overdrafts and short-term borrowings
|
| | | | 581 | | | | | | 581 | | |
Total
|
| | | | 2,258 | | | | | | 2,258 | | |
Non-current loans and borrowings
|
| | | | | | | | | | | | |
Non-current installments of loans and bonds
|
| | | | 17,410 | | | | | | 17,410 | | |
Non-current installments of leases
|
| | | | 464 | | | | | | 464 | | |
Notes offered hereby
|
| | | | | | | | | | | | |
AZ PLC 2023 Notes(2)
|
| | | | — | | | | | | 1,397 | | |
AZ PLC 2051 Notes(2)
|
| | | | — | | | | | | 735 | | |
AZ Finance 2024 Notes(3)
|
| | | | — | | | | | | 1,598 | | |
AZ Finance 2026 Notes(2)
|
| | | | — | | | | | | 1,246 | | |
AZ Finance 2028 Notes(2)
|
| | | | — | | | | | | 1,244 | | |
AZ Finance 2031 Notes(2)
|
| | | | — | | | | | | 747 | | |
Total
|
| | | | 17,874 | | | | | | 24,841 | | |
Equity
|
| | | | | | | | | | | | |
Share capital
|
| | | | 328 | | | | | | 328 | | |
Share premium account
|
| | | | 7,976 | | | | | | 7,976 | | |
Other reserves
|
| | | | 2,037 | | | | | | 2,037 | | |
Retained earnings
|
| | | | 4,089 | | | | | | 4,089 | | |
Total
|
| | | | 14,430 | | | | | | 14,430 | | |
Non-controlling interests
|
| | | | 16 | | | | | | 16 | | |
Total
|
| | | | 14,446 | | | | | | 14,446 | | |
Total capitalization
|
| | | | 34,578 | | | | | | 41,545 | | |
Notes
|
| |
ISIN
|
| |
CUSIP
|
|
AZ PLC 2023 Notes | | | US046353AY48 | | | 046353 AY4 | |
AZ PLC 2051 Notes | | | US046353AZ13 | | | 046353 AZ1 | |
AZ Finance 2024 Notes | | | US04636NAC74 | | | 04636N AC7 | |
AZ Finance 2026 Notes | | | US04636NAA19 | | | 04636N AA1 | |
AZ Finance 2028 Notes | | | US04636NAE31 | | | 04636N AE3 | |
AZ Finance 2031 Notes | | | US04636NAB91 | | | 04636N AB9 | |
| | |
AZ PLC
2023 Notes |
| |
AZ PLC
2051 Notes |
| |
AZ
Finance 2024 Notes |
| |
AZ
Finance 2026 Notes |
| |
AZ
Finance 2028 Notes |
| |
AZ
Finance 2031 Notes |
| ||||||||||||||||||
Goldman Sachs & Co. LLC
|
| | | $ | 140,000,000 | | | | | $ | 75,000,000 | | | | | $ | 160,000,000 | | | | | $ | 125,000,000 | | | | | $ | 125,000,000 | | | | | $ | 75,000,000 | | |
J.P. Morgan Securities LLC
|
| | | $ | 280,000,000 | | | | | $ | 150,000,000 | | | | | $ | 320,000,000 | | | | | $ | 250,000,000 | | | | | $ | 250,000,000 | | | | | $ | 150,000,000 | | |
Morgan Stanley & Co. LLC
|
| | | $ | 350,000,000 | | | | | $ | 187,500,000 | | | | | $ | 400,000,000 | | | | | $ | 312,500,000 | | | | | $ | 312,500,000 | | | | | $ | 187,500,000 | | |
Barclays Capital Inc.
|
| | | $ | 126,000,000 | | | | | $ | 67,500,000 | | | | | $ | 144,000,000 | | | | | $ | 112,500,000 | | | | | $ | 112,500,000 | | | | | $ | 67,500,000 | | |
BNP Paribas
|
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Citigroup Global Markets Inc.
|
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Deutsche Bank Securities Inc.
|
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
HSBC Securities (USA) Inc.
|
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Mizuho Securities USA LLC
|
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Santander Investment Securities
Inc. |
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Skandinaviska Enskilda Banken
AB (publ) |
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Société Générale
|
| | | $ | 63,000,000 | | | | | $ | 33,750,000 | | | | | $ | 72,000,000 | | | | | $ | 56,250,000 | | | | | $ | 56,250,000 | | | | | $ | 33,750,000 | | |
Total
|
| | | $ | 1,400,000,000 | | | | | $ | 750,000,000 | | | | | $ | 1,600,000,000 | | | | | $ | 1,250,000,000 | | | | | $ | 1,250,000,000 | | | | | $ | 750,000,000 | | |
| | |
Paid by Us
|
| |||
Per AZ PLC 2023 Note
|
| | | | 0.100% | | |
Per AZ PLC 2051 Note
|
| | | | 0.650% | | |
Per AZ Finance 2024 Note
|
| | | | 0.125% | | |
Per AZ Finance 2026 Note
|
| | | | 0.225% | | |
Per AZ Finance 2028 Note
|
| | | | 0.275% | | |
Per AZ Finance 2031 Note
|
| | | | 0.325% | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 5 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 14 | | | |
| | | | 31 | | | |
| | | | 35 | | | |
| | | | 35 | | | |
| | | | 37 | | | |
| | | | 44 | | | |
| | | | 46 | | | |
| | | | 46 | | |
(In millions of dollars)
(unaudited) |
| |
Year ended
December 31, 2020 |
| |
Three months ended
March 31, 2021 |
| ||||||
Total revenue
|
| | | $ | — | | | | | $ | — | | |
Gross profit
|
| | | | — | | | | | | — | | |
Operating loss
|
| | | | (45) | | | | | | (20) | | |
Loss for the period
|
| | | | (663) | | | | | | (166) | | |
Transactions with subsidiaries that are not issuers or guarantors
|
| | | $ | 2,637 | | | | | $ | 2,148 | | |
| | |
At December 31, 2020
|
| |
At March 31, 2021
|
| ||||||
Current assets
|
| | | $ | 26 | | | | | $ | 28 | | |
Noncurrent assets
|
| | | | 4 | | | | | | 4 | | |
Current liabilities
|
| | | | (1,720) | | | | | | (1,656) | | |
Noncurrent liabilities
|
| | | | (17,161) | | | | | | (17,072) | | |
Amounts due from subsidiaries that are not issuers or guarantors
|
| | | | 7,011 | | | | | | 6,243 | | |
Amounts due to subsidiaries that are not issuers or guarantors
|
| | | $ | (290) | | | | | $ | (295) | | |
|
AstraZeneca PLC
The Company Secretary 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA England Tel. No.: +44-20-3749-5000 |
| |
AstraZeneca PLC
Investor Relations 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA England Tel. No.: +44-20-3749-5000 |
|
Z
M ".P-G9OPO+ 9)A[C @T@Y5@YUQ>N5U7=.76-J)H!8.G&ET];-JW+
M'6X5^YC;F;2H,@GY>&3.BHMJ5$MCOGK9F(YP;"D10H"8H%$"C<+"TMY@ULS2
M2[0F6;OL_5Q-;DZ._+9M>Z]+LZAD.XFZGL+><-;/:B/7)$9&C28B_0I0^90,
MW XUEAUE^NG9G2MIU9\);<+:.H^MLS:]NW++6>R0G!C;26G+?2FUE+@=>+L&
M:I>)*-Z%1D /1R&^AA"WWFVR1K(]IY>M "1ECF!BF%8SL'88]1;C)'N3;R&S
M8UY!;+ UY+'B/ .8Y HQ;C@04(7$;TU?6DZP.L?KBM/1;4.-TCA;*N:WKGE
MU8RT8"]62(.HBS;ZG4J.YC42X627O[>1V'[PTH&T0Q73[;';VKK@ ZFHF(.!
M('#CC5[[I]D^B>D[&2YM+C 8;/4ROV#E3,"HF"61=D.( 0A@VU H[,8Q)#)KQ":78^"@U'
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M;=K1'7BU?'D6,BP4N",U#BY1\TY*!=@:49P5P6_?,;;[Y=ZBJO>C*6E?A:#-Z547!D D"D465S*JM%'!LO,$ 0"H=F7%][I?E\W+M#*ZZWA]
MA(>9';_ZO-(,L7/!(EBB" ,0\53 YU@?;CN!>;BKRY[8A&]/)'BD@%8ZES
M-VBRY-@M3-#EH-=H.T0V5_+B.$H=M_5UFV$AIY3SAC]R8?>K??5C@^QE!Q5C
M/_Q!4W^B$JJ]T>M5\<1$ZEGP@U[M:IP;<=P=W>;'Z$?RY.<_M3MLKBKOD&W'
M_P"$KS4[HAL74URUF1N)C]+Z[,CW)E6A:B-
V*:L=IA2F%
M*84IA2F%*_&6IK&B9JFS706O\KB6C5AH)PQ'$',95J1\A"7#4U ?I^NL.^HG1EZ
M@X3U3TZX<=>T LYE)%L19P*,DFFH@_*59(Z;MOF2,T4 !,H#Q!KLW1Q[Q]H
MAM19UMLC((I+$W5Z\\R9TA,>B=IC8X.C+AI=Y7%K5(&2IM3HWJ'YZ6]-[DY8
MWMC@;J :T!X,95S4>APQ )P/&N,6_P!6,!)6&YC[R%RUN*'34),,4T&)4554
MEE2)F24*Y05$1;J)B-2D"HCC1EC^8>]ZEM_Y$,EW\?:-,Y>^"V;$0J(',)>7
M?CC L P=C@%R3J'H&3HR^9N\3HC;.\@EFK*1H">4\:CXMF,6D9F%C@
MI[R99('H(B40570(;;3-02CCSQ[%]%W_ %=UA:3V+X Q\L[$D<]I5ML]Y(T,
M=@A\?94INXMXFTS28HV%A/LE6IO'4[ Z965#%G'01\3#0B+==RGE$2$C ,
MQ"F.=,:'(F--H;L>WUOW V#LWVTLF;U%=R2P;*P'X9K)%-I:LUZ>=+%B2?(J
M*<]-0'W"T.^;O)*S3^).2%)'OO/[H/M^JHUM=NI][>RSN&M4CAK;I72/+/"%
M;U?%39F25SFXBYZ"NHM@DYD4G^4E!!$VG! . K%(%" AM
M ?T[]G:./.=FVW,TH8'-Q]? +X5*;Y=+&%5J>W]EZY=*NKSI_
MN?7G2"683:4!#2Z[F!=L9E&=:RD3%M9=(DLW>MXI8[$4!#AID&M:&[ LMV
MTQ_A.0-.(3+Z,^%19ZFZ ?TEU%;[;=N<99+
I?#C6>FC?1VJ_BD9_4A=V0':2H%MU:)6(=L(.1*13FW#L!.(I(B-.7+L4W
M[-OHYVG_ "7;?U%M\&Z[\Z"U,D,$WNZ>VZDGD5Q<\!>*)]'"H*=<./\P7-U(/,^5K<
M,?=C#>*8>6LBV*!6J M'RA%U7)S'.5+NI@0A"G'V2HFV"D([ QT-C!.O'5QK
M"[&UN[1NMSFX%4G@*B!ZV?6>Z5.B*7E[#?J79>VJ#8TR@2U[7C[?=MHQ[#
M'!N#>56E;M@G"8O':X$3R)K5X1ZY:!FO-ILL]TCR6AF&"E9]M;1Z:Z%W7K
M%[#&^W:!RP2YSP3S
T+IR<,R+)OXM*JQ;HR1:N@*\E[G10*(9
MR@:E0 $<7;:"URQXZ@57AD*E!V"OX8KEMA(?Q!/*]4. , :!AAFT_36N_#0
M:WQKVS-7M$'4BU1N"UYS3VYH"+6XI'$O%W>YO]R\:$.80:G/%H1"!* 8@E%8
M,P#4*5F\PNT1R(C H)PP5$/CXY5=?S#0OEL[:5K-36MNU/@HBT_2A7U8I5M5
MO)%,9 $T\K=PL=)(!*:J3DAE"* ;^J4#IG[PAE^O:&,-W&SD>Y<7.)'$! F>
M/L^G*H9PW)CDT. #,CBX!&'C7J7H-_U1%(E1S'S".P*;"UV[ [,:HV
M>S?8VSHI 02\G$@Y@#AZJ\NV$Q'S(H.Q;H+5$C-5(X@%/O$CD%/,%!$
MP9D^S%1I^*F"9Q.7Z_3ZJM\X;(X-.9
W8Y67\,